GlassScriptPhysician profile
Ian Chiu
NPI 1477147585
$14,202.06
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.41 · 2023: $549 · 2024: $1,532 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,665 · Consulting Fee: $4,046 · Food and Beverage: $3,557 · Travel and Lodging: $1,894 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,665.00 |
| Consulting Fee | $4,046.00 |
| Food and Beverage | $3,557.18 |
| Travel and Lodging | $1,893.87 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,148.97 | 2023-2025 | Tavneos, Uplizna, Krystexxa |
| Apellis Pharmaceuticals, INC. | $4,992.94 | 2025 | Empaveli |
| Travere Therapeutics, INC. | $1,092.06 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $377.20 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $238.82 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $225.01 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $224.79 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.20 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $184.54 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $164.14 | 2024-2025 | Benlysta |
| Genzyme Corporation | $93.49 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $68.35 | 2024-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $36.10 | 2024 | Acthar |
| Daiichi Sankyo INC. | $26.41 | 2022 | |
| Lilly USA, LLC | $25.38 | 2024 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $23.05 | 2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $22.87 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.84 | 2025 | Tryvio |
| Novo Nordisk INC | $17.58 | 2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2024 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.